Had you bought the stock at the end of 2014, your yield—based on a $1.08 annualized dividend and a then-prevailing price of $34.75—would have been 3.11%. But each year after that, CMS increased its ...
There are several limitations to the CMS negotiation approach illustrated in this example, starting with the dubious implicit assumption that the prices for therapeutic alternatives will be fair. Once ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results